A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK, now under development and close to clinical trials. The book captures-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.

Includes supplementary material: sn.pub/extras

Klappentext

Because of drug resistance, currently available anticancer therapies-drugs, radiotherapy, and other biological agents-have limited efficacy in treating cancer. In DNA Repair in Cancer Therapy, leading cancer researchers and oncologists comprehensively review the many recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limit its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Inhibitors of such other DNA repair enzymes as PARP and DNA-PK, now under development and close to clinical trials, are also examined.
Comprehensive and cutting-edge, DNA Repair in Cancer Therapy surveys-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.

Inhalt
Content.- 1 Clinical Resistance to Alkylators: Status and Perspective.- 2 Role of Nonhomologous End-Joining and Recombinational DNA Repair in Resistance to Nitrogen Mustard and DNA Crosslinking Agents.- 3 Repair of DNA Interstrand Crosslinks Produced by Cancer Chemotherapeutic Drugs.- 4 Chemosensitization to Platinum-Based Anticancer Drugs: Current Trends and Future Prospects.- 5 Regulation of DNA Repair and Apoptosis by p53 and Its Impact on Alkylating Drug Resistance of Tumor Cells.- 6 Stress-Activated Signal Transduction Pathways in DNA Damage Response: Implications for Repair, Arrest, and Therapeutic Interventions.- 7 Overcoming Resistance to Alkylating Agents by Inhibitors of O6-Alkylguanine-DNA Alkyltransferase.- 8 Cellular Protection Against the Antitumor Drug Bleomycin.- 9 Potential Role of PARP Inhibitors in Cancer Treatment and Cell Death.- 10 Relationship Among DNA Repair Genes, Cellular Radiosensitivity, and the Response of Tumors and Normal Tissues to Radiotherapy.- 11 Strand-Break Repair and Radiation Resistance.- 12 V(D)J Recombination and DNA Double-Strand-Break Repair: From Immune Deficiency to Tumorigenesis.- 13 Inherited Disorders of Genomic Instability and Cancer Susceptibility.- 14 Role of BRCA1 and BRCA2 in DNA Repair and Potential Impact on Therapeutics.- 15 Genetic Variations in DNA Repair: Their Implications in Human Cancer Risk, Prevention, and Therapy.